{"filing":{"accession_number":"0001193125-26-305400","cik":"0001885827","ticker":"VRAX","company_name":"Virax Biolabs Group Ltd","form":"6-K","filing_date":"2026-07-16","report_date":null,"primary_document":"6-k_7.16.26_shareholder_.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885827/000119312526305400/6-k_7.16.26_shareholder_.htm"},"events":[{"id":18283,"run_id":16431,"accession_number":"0001193125-26-305400","anchor_item_number":"EX-99.1","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"This exhibit bundles multiple material developments: (1) fiscal 2026 annual report filing with audited financials showing $6.4M cash and $7.3M shareholders' equity; (2) a commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets; (3) completion of a preferred investment option exercise generating $3.3M in gross proceeds; and (4) Nasdaq compliance restoration following a 1-for-25 share consolidation. While each component is material (financing, commercial progress, regulatory compliance), the exhibit is a CEO shareholder update synthesizing multiple discrete events rather than a single classified event type. The financing and commercial agreement are most significant, but the exhibit's primary function is to contextualize the annual report filing and provide strategic commentary rather to announce a single discrete transaction.","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-07-16","form":"6-K","submitted_at":null,"items":[{"id":17047,"accession_number":"0001193125-26-305400","item_number":"EX-99.1","item_title":"vrax-ex99_1.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This exhibit bundles multiple material developments: (1) fiscal 2026 annual report filing with audited financials showing $6.4M cash and $7.3M shareholders' equity; (2) a commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets; (3) completion of a preferred investment option exercise generating $3.3M in gross proceeds; and (4) Nasdaq compliance restoration following a 1-for-25 share consolidation. While each component is material (financing, commercial progress, regulatory compliance), the exhibit is a CEO shareholder update synthesizing multiple discrete events rather than a single classified event type. The financing and commercial agreement are most significant, but the exhibit's primary function is to contextualize the annual report filing and provide strategic commentary rather to announce a single discrete transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:59.696838+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17047,"accession_number":"0001193125-26-305400","item_number":"EX-99.1","item_title":"vrax-ex99_1.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This exhibit bundles multiple material developments: (1) fiscal 2026 annual report filing with audited financials showing $6.4M cash and $7.3M shareholders' equity; (2) a commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets; (3) completion of a preferred investment option exercise generating $3.3M in gross proceeds; and (4) Nasdaq compliance restoration following a 1-for-25 share consolidation. While each component is material (financing, commercial progress, regulatory compliance), the exhibit is a CEO shareholder update synthesizing multiple discrete events rather than a single classified event type. The financing and commercial agreement are most significant, but the exhibit's primary function is to contextualize the annual report filing and provide strategic commentary rather to announce a single discrete transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:59.696838+00:00","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-07-16"}]}